Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient...

French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, pr...

Sanofi announces buy back of shares from L'Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L'Oréal.

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Sanofi (NASDAQ:SNY ) Q4 2024 Results Conference Call January 30, 2025 9:00 AM ET Company Participants Thomas Larsen - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger...

SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025.

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it...

Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma

Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi's Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold...

Sanofi's Sarclisa SC formulation shows non-inferiority versus Sarclisa IV infusion in a late-stage study for treating relapsed, refractory multiple myeloma.

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Sanofi's Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 billion,...

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary en...

Sanofi's SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the p...